Abstract:Klisyri (KX01) is a dual tubulin/Src protein inhibitor that has shown potential therapeutic effects in several tumor models. However, a phase II clinical trial in patients with bone-metastatic castration-resistant prostate cancer was halted because of lack of efficacy. We previously reported that KX01 binds to the colchicine site of β-tubulin and its morpholine group lies close to α-tubulin's surface. Thus, we hypothesized that enhancing the interaction of KX01 with α-tubulin could increase tubulin inhibition and synthesized a series of KX01 derivatives directed by docking studies. Among these derivatives, 8a exhibited more than 10-fold antiproliferation activity in several tumor cells than KX01 and significantly improved in vivo antitumor effects. The X-ray crystal structure suggested that 8a both bound to the colchicine site and extended into the interior of α-tubulin to form potent interactions, presenting a novel binding mode. A potential clinical candidate for cancer therapy was identified in this study.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01961?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01961</a>.Characterization of key compounds, antiproliferation activity data, MTD, table of protein crystal data collection and refinement statistics, and HPLC purity traces for key final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_001.pdf">PDF</a>)Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_002.csv">CSV</a>)Structural data for compounds 6a, 6d, and 6r (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_003.pdb">PDB</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_004.pdb">PDB</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_005.pdb">PDB</a>)This article has not yet been cited by other publications.

Studying drug-tubulin interactions by X-ray crystallography

The X-ray structure of tubulysin analogue TGL in complex with tubulin and three possible routes for the development of next-generation tubulysin analogues

Computational Approaches to the Rational Design of Tubulin-Targeting Agents

Drug design and synchrotron

In Silico Exploration of Novel Tubulin Inhibitors: A Combination of Docking and Molecular Dynamics Simulations, Pharmacophore Modeling, and Virtual Screening

Discovery of Novel Tubulin Polymerization Inhibitors by Utilizing 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation

Structural Insights Into The Pharmacophore Of Vinca Domain Inhibitors Of Microtubules

Combined Molecular Docking, 3D-QSAR, and Pharmacophore Model: Design of Novel Tubulin Polymerization Inhibitors by Binding to Colchicine-binding Site.

Drugs that target dynamic microtubules: A new molecular perspective

Podophyllotoxin derivatives-tubulin complex reveals a potential binding site of tubulin polymerization inhibitors in α-tubulin adjacent to colchicine site

X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor

Synthesis and biological evaluation of novel indole derivatives containing sulfonamide scaffold as potential tubulin inhibitor

Protein X-ray Crystallography and Drug Discovery

Exploration of anti-tumour inhibitors from colchicine derivatives based on 3D-QSAR, molecular docking and molecular dynamics simulations

High-affinity ligands of the colchicine domain in tubulin based on a structure-guided design

Exploring serial crystallography for drug discovery

Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure

Discovery and mechanistic insights into thieno[3,2-d]pyrimidine and heterocyclic fused pyrimidines inhibitors targeting tubulin for cancer therapy

Discovery of novel microtubule stabilizers targeting taxane binding site by applying molecular docking, molecular dynamics simulation, and anticancer activity testing

Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action

Qsar And Molecular Docking Study Of A Series Of Combretastatin Analogues Tubulin Inhibitors